Support Programs to Help Make Ig Therapy Accessible and Affordable

The majority of Hizentra patients with commercial insurance pay $0 out-of-pocket

The Hizentra Co-Pay Relief program helps eligible patients with monthly out-of-pocket expenses for Hizentra (up to $5,000 per year, with no monthly cap*).^†

• Prescription must be for chronic inflammatory demyelinating polyneuropathy or primary immunodeficiency diagnosis. For PI diagnosis, patients must be at least 2 years of age and for CIDP diagnosis, patients must be at least 18 years of age
• Patient must be receiving Hizentra through a specialty pharmacy or physician office
• It is recommended that the patient use a Specialty Pharmacy provider that is in-network with the patient's current plan
• Patient must express financial need
• Patient must have coverage for the product under a private U.S. insurance plan. Not valid for prescriptions eligible for reimbursement by any federal or state healthcare program, such as Medicare, Medicare Advantage plans, Medicaid, PCIP, Champus, TriCare, Veterans Administration (VA), or any other state or federal program

• Patients whose insurance policy prohibits co-pay assistance are not eligible. Prior to enrolling in this CSL Behring program, participants are responsible for checking with their insurance carrier to confirm that their participation is not inconsistent with their insurance carrier's requirements.
• This program is subject to change or discontinuation by CSL Behring at any time, for any reason, and with or without prior notice

Enrollment happens seamlessly at the Specialty Pharmacy. Patients interested in receiving co-pay assistance must contact their Specialty Pharmacy, express their need for financial assistance, and ask the pharmacy to enroll them by requesting Hizentra Co-Pay Assistance.*

Patients can contact CSL Behring's IgIQ Resource Center at 1-877-355-IGIQ (4447).

Protect your patient from a lapse in coverage

A gap in insurance shouldn't mean a gap in treatment. CSL Behring understands the stress and hardship caused by a lapse in health insurance. CSL Behring Assurance^SM is designed to help eligible patients, who rely on our Ig therapies, continue to receive treatment even if they experience a lapse in third-party, private health insurance.

Benefits for Patients

CSL Behring Assurance allows patients to build up a reserve of Hizentra at no additional cost. This can be used in the event of a lapse in insurance coverage, so it's important to enroll as soon as possible.^‡

Advantage for HCPs

CSL Behring Assurance helps to keep patients on track with their treatment protocol during difficult times.

• A unique program that connects PI and CIDP patients and caregivers with people who have direct experience with Hizentra therapy